Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2023-05-12 Interim / Quarterly Rep…
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PHN- INTERIM FINANCIAL REPORT AS AT MARCH 31,2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM MANAGEMENT REPORT' and 'CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 MARCH 2023'. It contains detailed financial tables, including the consolidated balance sheet, income statement, and cash flow statement for the period ending March 31, 2023. Since it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). Q1 2023
2023-05-12 English
PHN - RESOCONTO INTERMEDIO DI GESTIONE AL 31.3.23
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RESOCONTO INTERMEDIO DI GESTIONE AL 31 MARZO 2023' (Interim Management Report as of March 31, 2023). It contains comprehensive financial data, including consolidated balance sheets, income statements, cash flow statements, and management commentary for the first quarter of 2023. It is a formal financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-12 Italian
PR - PHARMANUTRA - PHN - Approval of interim report as of 31 march 2023
Interim / Quarterly Report Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. announcing the approval of its interim management statement for the period ending March 31, 2023. It contains substantive financial data, including consolidated income statements, balance sheets, and analysis of results. While it is titled as a press release, it provides the actual financial data for the interim period rather than just announcing the availability of a separate report. Therefore, it qualifies as an Interim/Quarterly Report (IR). Q1 2023
2023-05-08 English
CS PHARMANUTRA - PHN - Approvazione resoconto intermedio di gestione al 31 marzo 2023
Interim / Quarterly Report Classification · 1% confidence The document is a detailed financial report for the period ending March 31, 2023, titled 'Resoconto Intermedio di Gestione' (Interim Management Report). It contains comprehensive financial data, including consolidated balance sheets, income statements, and cash flow statements, as well as management's analysis of results and future outlook. Although it is presented as a press release, it provides the actual substantive financial data and analysis required for an Interim/Quarterly Report (IR) rather than just an announcement of a report. Q1 2023
2023-05-08 Italian
PHN - Rendiconto sintetico votazioni Assemblea 27 aprile 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document header explicitly states 'Informazione Regolamentata' (Regulated Information) and the 'Oggetto' (Subject) is 'PHN - Rendiconto sintetico votazioni Assemblea 27 aprile 2023' (PHN - Summary report of voting results Annual Meeting April 27, 2023). The body of the text details the voting results ('Rendiconto sintetico delle votazioni') for various agenda items discussed at the 'ASSEMBLEA ORDINARIA DEGLI AZIONISTI DEL 27 APRILE 2023' (Ordinary Shareholders' Meeting of April 27, 2023). This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting.
2023-05-04 Italian
PHARMANUTRA - PR - PHN - ORDINARY SHAREHOLDERS MEETING AND BOD RESOLUTIONS 26 04 2023
AGM Information Classification · 1% confidence The document is an official announcement dated April 26, 2023, detailing the resolutions passed during the Ordinary Shareholders' Meeting (Assemblea Ordinaria degli Azionisti). Key resolutions include the approval of the 2022 financial statements, dividend distribution, approval of the Remuneration Policy, appointment of the Board of Directors, and authorization for treasury share purchases. The subject line explicitly mentions 'RESOLUTIONS 26 04 2023' and 'ORDINARY SHAREHOLDERS' MEETING'. While it discusses financial results and remuneration reports, the primary purpose of this specific filing is to report the outcomes and decisions made at the general meeting. This aligns best with the 'AGM Information' category, which covers presentations and materials shared during the AGM, as this document summarizes the key outcomes of that meeting.
2023-04-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.